


BOOK EARLY AND
SAVE \$400

May 8 – 10, 2018, Boston, MA

www.3d-oncology.com



3D Tissue Models Oncology 2018

Empowering Cancer Drug Research Through the Application of 3D Tissue Models

Expert Speakers Including:



Jason Ekert
Head of Complex *In Vitro*
Models
GlaxoSmithKline



Susan Kaufman
Sr. Scientific Researcher
Genentech



Timothy Spicer
Assistant Professor -
Molecular Medicine &
Associate Scientific Director
Scripps Institute



Silvia Goldoni
Investigator III &
Head of Oncology Lab
**Novartis Institutes
for Biomedical
Research**



Brett Hall
CEO
Asellus



Christopher Heery
CMO
Bavarian Nordic

EXPERTISE PARTNERS:

MITRABIOTECH 

RIGENERAND
Steps Ahead In Cell Technology



EXHIBITION PARTNERS:


greiner bio-one

Tel: +1 617 455 4188 Mail: info@hansonwade.com

 3D Tissue Models: Drug Discovery & Development



Welcome to the Only Industry Driven Event Focused on Realizing the Practical Applications of 3D Tissue Models in Oncology

3D Tissue Models is a dedicated conference series that explores a singular theme: **The true utility and applicability of 3D Tissue Models within biopharmaceutical research.**

Representing the first disease-area specific expansion of this series, 3D Tissue Models: Oncology has been collaboratively designed and developed with over 30 major biopharmaceutical organizations. Driven through pharmaceutical insights of early adopters, the meeting will explore and **address the variety of technical and cultural concerns and challenges including; platform utility, validity, standardization, scaling and automation.**


It will facilitate an environment that enables open and interactive debate to ensure thought-provoking discussions and unparalleled networking opportunities for all attendees.

Our mission is to reinvigorate drug discovery and development by providing a forum that **unites leading pharmaceutical scientists, model developers & academic leaders to** explore the advent of the variety of models now at our fingertips. You will have the opportunity to join leading experts to openly debate the translational, organizational and development barriers preventing platform adoption and use.

PREVIOUS ATTENDEES INCLUDE




INTERACTIVE OPPORTUNITIES



Key Case Studies Not to Miss

1.

Bavarian Nordic
exploring cultural barriers to update their preclinical strategies by integrating 3D models into the discovery paradigm and enabling better ID and validation of oncology targets



2.

Scripps Institute
revealing novel chemotherapeutic activities of screened libraries discerned through their industrialized and fully automated 1536 well compatible HTS platforms



3.

Merck & Pfizer
demonstrating the opportunities for 3D models in evaluating donor differential responses, biomarker discovery and patient stratification



4.

Roche Pharmaceuticals
exploring the need to shift from 'diffusion' to 'perfusion' and revealing the utility of microfluidic and static-based 3D cultures in preclinically assessing immune-modulatory drugs



5.

GSK & Dana-Farber Cancer Institute
addressing core challenges in the development and validation of 3D tumor models in preclinical discovery and assessment of tumor cell killing



Your Expert Speakers



Brett Hall
CEO
Asellus



Christopher Heery
CMO
Bavarian Nordic



Cristina Bertinetti-Lapatki
Lab Head
Mechanistic Safety
Roche Pharmaceuticals



Eugen Dhimolea
Research Fellow,
Medical Oncology
Dana-Farber Cancer Institute



Geoffrey Bartholomeusz
Associate Professor
& Director, Target
Identification and
Validation Program
M.D.Anderson Cancer Center



Hongmin Chen
Principal Scientist
Merck & Co



Jason Ekert
Head of Complex In
Vitro Models
GlaxoSmithKline



Mark Kaplan
Translational
Oncology Lead
Pfizer



Mark Paris
Associate Director,
Translational
Applications
Mitra Biotech



Roger Kamm
Cecil and Ida Green
Distinguished
Professor of
Mechanical and
Biological Engineering
MIT



David Barbie
MD
Assistant Professor
of Medicine
Dana-Farber Cancer Institute/ Harvard Medical School



Shawn Hingtgen
Assistant Professor
UNC Eshelman School of Pharmacy



Silvia Goldoni
Investigator III &
Head of Oncology
Lab
Novartis Institutes for Biomedical Research




Susan Kaufman
Senior Scientific
Researcher
Genentech



Svetlana Sadekova
Senior Principal
Scientist & Head
of Translational
Pathology Group
Merck & Co



Timothy Spicer
Assistant Professor -
Molecular Medicine
& Associate
Scientific Director
Scripps Institute



Dan Gioeli
Associate Professor,
Microbiology,
Immunology, and
Cancer Biology
University of Virginia



Olivia Candini
Cell and Tissue
Engineering R&D
Manager
Rigenerand srl

Pre-Conference Workshop Day | May 8th

Workshop A

Leveraging Clinically Relevant 3D Models That Recapitulate the Tumor Microenvironment

9.00am – 12.00pm

The tumor microenvironment (TME) is a complex system comprising a multitude of cellular components such as tumor cells, endothelial cells, fibroblasts, immune cells, and stellate cells, as well as a complex extracellular matrix (ECM) whose precise interactions are essential for the growth of primary tumors and subsequent metastasis. Targeting essential molecular drivers within these cellular components including those of the cancer cells pose potential targets for therapeutic intervention. Identifying these targets is dependent on our ability to develop pre-clinical models that recapitulate the tumor microenvironment and whose molecular signature is highly correlated with that of the original tumor.

Traditional in-vitro 2D preclinical models do not accurately predict efficacy or safety of anticancer therapies in humans. New in-vitro preclinical 3D models including spheroids, organoids, Induced pluripotent stem cell (iPS) models, and novel ex vivo systems, all of which have promise are being developed to address the deficiencies in traditional 2D models.

This workshop focuses on 3D systems, including spheroids, organotypic tumor models, novel ex vivo systems, and patient derived xenografts to study characteristics of the TME, and how these 3D systems can be leveraged for the drug discovery and evaluation process. Attendees will be provided with a robust primer on the systems in use which will enhance the value of the main meeting.

Join this session to leave having:

- Identified the role played by the microenvironment in modulating drug responses
- Evaluated potential therapeutic targets within the tumor microenvironment
- Assessed state-of-the-art in vitro tumor models
- Identified the outstanding questions in the field

“I thought the conference was very focused. It was time well spent. I learned a lot and had productive networking sessions”

Hicham Alaoui, Director, Biochemical & Cellular Pharmacology, Genentech, 3D Tissue Models Attendee



Workshop Leader

Dan Gioeli, Associate Professor, Microbiology, Immunology, and Cancer Biology, **University of Virginia**

Dr Gioeli is currently an Associate Professor at the University of Virginia where the goals of his research are to understand the mechanistic underpinnings of the cell signaling network that contribute to cancer progression and resistance to therapy. His group are identifying signaling pathways that compensate for androgen ablation in prostate cancer, looking for combinatorial therapeutic targets in a variety of solid tumors, and developing a novel tumor microenvironment model to interrogate host-tumor interactions and evaluate cancer therapeutics. Previously Dr. Gioeli was Senior Director Cancer Biology at HemoShear where he was responsible for developing a first-in-class human tumor microenvironment system to advance the discovery and development of effective cancer therapeutics.



Workshop Leader

Geoffrey Bartholomeusz, Associate Professor & Director, Target Identification and Validation Program, **M.D.Anderson Cancer Center**

Geoffrey Bartholomeusz has worked extensively as a cancer biologist with expertise in both molecular biology and drug development. A goal of his research is to utilize high throughput siRNA screens in a 3D cell culture assay to identify novel targets regulating the tumor architecture. His hypothesis driven study proposes that altering the tumor architecture will lower the levels of hypoxia within solid tumors sensitizing these tumors to irradiation and/or chemotherapy. In an attempt to confirm this hypothesis his team has developed a 3D spheroid cell culture model that has similarities to hypoxic regions of solid tumors. As a member of a multi-investigator group within MD Anderson Cancer Center Dr. Bartholomeusz is also involved in developing a technology that will permit them to regenerate tumors in the lab utilizing biopsy tissue with the goal of developing cancer patient specific drug cocktails

Pre-Conference Workshop Day | May 8th

Workshop B

Showcasing the Advanced Technological Development of 3D Tissue Culture Models using Automated Platforms

2.00pm – 5.00pm

Given their ability to add human relevance earlier into the pipeline and increase physiological representation of the in vivo environment, 3D models hold a lot of promise for bridging the translational gap.

This increasing interest in studying the interactions between cells and the extracellular matrix (ECM) has created a need for high throughput and low cost 3D culture systems. However, whilst 3D tissue cultures gain acceptance and become more and more prevalent in drug screening, there is an ever growing need to overcome key challenges associated with scaling and automation of these cultures.

Whilst, spheroids and organoids have presented a simple model system, manipulations of these cultures are laborious and challenges are amplified as sample throughput increases. This session will explore current road blocks associated with model development, scaling and automation as well as reveal novel insights into the development of an ultra high throughput system using automated platforms.

Join this session to leave with:

- Engineering solutions from the benchtop to fully automated industrial scaled platforms
- Adaptation of critical 3D culture hardware
- Confirmation of the utility and possibility of 3D modeling using high content imaging
- Examples of fast and accurate full plate imaging or organoids/spheroids using in house engineered plate auditors
- Insights into acoustic transfer of drugs for drug reformulation and large scale synergy studies



Workshop Leader

Timothy Spicer, Assistant Professor
- Molecular Medicine & Associate
Scientific Director, **Scripps Institute**

Tim Spicer, is an Associate Director and Assistant Professor in the Department of Molecular Therapeutics and joined Scripps Florida in 2005. Tim has more than 27 years of experience in drug discovery, including 10 years at Bristol-Myers Squibb. Tim is currently the director of HTS and discovery biology and co-directs the screening center at Scripps. He supervises HTS assay development & related efforts including technology development for which he has NIH funding on the 3 year award for the Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells. He has authored >90 drug-discovery related publications and is an inventor on 3 patents, including clinically relevant antiviral compounds

Great organization, and venue.
Great networking opportunities and
plenty of time for it

3D Tissue Models 2017 Attendee



Turn the page to view the Main Agenda



Conference Day One | May 9, 2018

7.30 Registration & Networking

8.50 Chairs Opening Remarks

Overcoming Challenges for 3D Models in Preclinical Discovery & Assessing of Cytotoxic Effects of Oncology Drug Candidates

Shawn Hingtgen
 Assistant Professor
UNC Eshelman
School of Pharmacy

8.30 Overcoming Heterogeneity, 3D Screening Platforms to Identify Novel Drug & Drug Target Candidates for Brain Cancers

- Reviewing key aspects of stem cell therapy for brain cancer
- Demonstrating new models for assessing heterogeneous tumor responses to cell therapies
- Showcasing new strategies for overcoming tumor heterogeneity developed using new
- 3D culture and tissue-based systems

Jason Ekert
 Head Complex In
 Vitro Models
GSK

9.00 Addressing Development, Validation and Automation of 3D Solid Tumor Models in Preclinical Drug Discovery

- Highlighting opportunities and challenges in adoption of 3D solid tumor models in preclinical drug discovery
- What key components should be considered when developing a 3D solid tumor model that is more physiological relevant?
- How do we validate, scale and automate 3D solid tumor models in preclinical drug discovery?

Timothy Spicer
 Assistant Professor -
 Molecular Medicine
 & Associate Scientific
 Director
Scripps Institute

9.30 A Comparative Analysis of 3D Platforms in High Throughput Formats to Assess the Cytotoxic Effect of Drugs for Discovery

- Showcasing a fully automated 1536 well compatible platform able to perform HTS on large compound libraries
- Highlighting the applicability of 3D spheroid based uHTS assays for the purpose of testing molecules in a more phenotypically relevant format to cancer biology

10.00 Speed Networking & Morning Refreshments

In Vitro Constitution of Stromal Biology & Humanized TME to Support Anticancer Therapeutics

Mark Paris
 Associate Director,
 Translational
 Applications
Mitra Biotech

11.00 Transforming Translational Research: CANscript™ - A Better Predictive Model for Oncology

- Recreating the human TME by using fresh human tumour tissue, autologous serum and immune cells, and immune-targeted agents in a platform with 1:1 clinical outcome validated in over 2,000 patients
- Interrogate the phenotypic changes in living tissue in response to standard-of-care agents, PD-1 and PD-L1 inhibitors to explore compound activity, mechanism of action and discover & validate biomarkers
- Predict clinical efficacy and enrich clinical trials with responders



Brett Hall
CEO
Asellus

11.30 Terraforming the Tumor Microenvironment for Improved Drug Discovery & Optimal Clinical Translation

- Incorporate a greater degree of human-TME aligned complexity into in vitro and ex vivo models for improved discovery & translation of oncology drugs
- Enable humanized 3D, TME-aligned platforms to produce a more complex and pathophysiological model that more aptly reflects human cancer
- Discuss the benefits and diverse biological applications of 3D-TME models with or independent of patient derived xenografts models



Roger D. Kamm
Cecil and Ida Green
Distinguished
Professor of
Mechanical
and Biological
Engineering
**Massachusetts
Institute of
Technology**

12.00 Evaluating Cancer-Stromal-Immune Endothelium Interactions Through Vascularized 3D Tumor Microenvironment (TME) Models

- Utilizing tissue-engineered vascularized tumor microenvironments for modelling disease progression and treatment
- Highlighting the ability of vascularized tissue models to probe the arrest, transmigration and migration of circulating tumor cells in organ specific models
- Exploring how vascularized tumor microenvironments can serve as a platform for the testing of anticancer therapeutics
- The diagnostic potential of vascularized models

12.30 Lunch & Networking

3D Models Aiding Translational Immuno-Oncology Research



Susan Kaufman
Senior Scientific
Researcher
Genentech

1.30 Methods to Evaluate and Validate New Technologies for Advanced 3D In Vitro Immuno-oncology Models

- The pursuit of new therapies targeting the tumor microenvironment and the immune response has revealed a gap in relevant pre-clinical models and a need for new technologies to address it.
- Using a standardized immuno-oncology ex-vivo model to evaluate and validate emerging in vitro technologies allows a head to head comparison of how the models recapitulate the tumor, stroma, and immune components.
- A 3D gel-matrix bioprinted culture emerges as a multi-well option for an in vitro immuno-oncology model and demonstrates the effects of stiffness on tumor and stromal components.



Svetlana Sadekova
Senior Principal
Scientist & Head
of Translational
Pathology Group
Merck & Co

2.00 Human Tissue Based Preclinical Models for Biomarker Discovery and Translational Immune-Oncology

- Demonstrating how rapid advancement in immuno-oncology has created a need for translational strategies to guide indication selection, understand mechanisms of resistance and identify biomarkers of response
- Highlighting the importance of understanding human tumor microenvironment
- Revealing strategies based on utilizing ex vivo tumor explant cultures and cancer organoid-based models for translational research in immune-oncology



Olivia Candini
Cell and Tissue
Engineering R&D
Manager
Rigenerand srl

3.00 Mimicking in Vivo Complexity By The Innovative 3D Model VITVO®

- Introducing a novel platform to recreate a 3D tissue-like structure that allows a greater level of prediction of anti-tumor compound efficacy and toxicity
- Exploring VITVO® potentials for testing of different cell types in a variety of drug treatment approaches, including cells and gene therapies
- Highlighting VITVO® as a concrete solution between *in Vitro* and *in vivo* models to speed pre-clinical prediction within personalized medicine approaches

3.30 Afternoon Refreshment Break



Silvia Goldoni
 Investigator III &
 Head of Oncology
 Lab
**Novartis Institutes
 for Biomedical
 Research**

4.30 **Interrogating The Effect Of Targeted Therapies On Tumor Immunity In Vitro**

- Performing compound profiling of targeted IO combination therapies in 3D models to aid in-vitro in-vivo translation
- Analyzing immune suppressive features of co-culture
- Highlighting the applications of co-culture to profiling targeted therapies using multiple readouts



Christopher Heery
 CMO
Bavarian Nordic



Jason Ekert
 Head Complex In
 Vitro Models
GSK

5.00 **Discussion Panel: Collaborative Strategies to Lower the Barriers for Entry in Pharma**

- What role should big pharma play to help commercialize the field?
- What are the greatest opportunities and challenges in adoption of more predictive 3D models?
- What key components should be considered when developing a predictive 3D model?
- How does the Intellectual property and exclusivity landscape of 3D Models impede future development and adoption?
- What is the current regulatory landscape in oncology and what remains to be showcased for the next wave of regulatory considerations to take place?
- Does context of use for microphysiological systems remain a critical factor in achieving success within industry?

5.45 **Close of Conference Day One**



Scientific Poster Session

After the formal presentations have finished, the learning and networking carries on. No more sitting quietly, the Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

During this session scientific posters will be presented on 3D models validating innovative targets, disease models highlighting novel mechanisms and platforms enabling the effective prediction of clinical efficacy.

“The meeting was excellent. I was impressed with the array of highly relevant experts that were brought together to speak”

**Andreas Baudy, Associate Principal
 Scientist, Merck, 3D Tissue Models
 Attendee**



Conference Day Two | May 10, 2018

8.50 Chairs Opening Remarks

Characterizing the Utility of 3D Models in Oncology and IO Research



9.00 Requirements for Improved Preclinical Models for More Rapid Clinical Development in Immuno-Oncology

- From 2D to 3D to mice showcasing the inefficiencies of preclinical models in IO therapy as inadequate in selecting optimal combination strategies
- Exploring the ideal characteristics of a model for preclinical assessment of cancer immunotherapy
- Highlighting a need to shift business models to allow therapeutic companies to evaluate these models with lower risk



9.30 3D In Vitro Systems for Translational Oncology: Opportunities and Challenges

- Preclinical systems (cell lines, patient-derived xenografts) can be used to develop hypothesis for clinical biomarkers, but there are limitations
- Complex *in vitro* biological systems can potentially have an important place, particularly for immune-oncology
- It is important to build confidence in the translatability of complex *in vitro* biological systems

10.00 Morning Refreshments and Networking

Utilizing 3D Models to Profile Sensitivity and Resistance



11.00 Ex-Vivo Profiling of Response to PD-1 Blockade Using Organotypic Tumor Spheroids

- Murine-derived organotypic spheroids from well-established syngeneic models retain autologous immune cells and recapitulate response/resistance to immune checkpoint blockade
- Specific combination therapies that overcome resistance to PD-1 blockade *ex vivo* can be validated *in vivo*
- *Ex vivo* culture of patient-derived organotypic spheroids also reveals heterogeneous responsiveness to PD-1 blockade, and may represent a valuable tool to guide functional precision immune-oncology



11.30 Ex Vivo Patient Derived 3D Models To Assess Drug Resistance and Therapeutic Efficacy

- Evaluating clinically relevant *ex vivo* 3D drug response assays and complex, 3D co-culture micro-tumor models using patient matched immune components
- Enable experimentally guided restored human TME's to produce a more complex and physiological relevant model to accurately represent cancer
- Discussing benefits and diverse biological applications of TME models over patient derived xenografts models

12.00 Lunch & Networking

Utilizing Advanced In Vitro Models to Assess Patient Specific Responses



1.00 Development and Validation of a Novel Multicellular Human 3D Tumor Microenvironment System

- Describing the development and validation of a novel multi-cellular 3D *in vitro* system for pancreatic cancer and non-small cell lung carcinoma
- Recreating multiple aspects of cancer biology through the combination of microvascular endothelial cells exposed to tumor hemodynamics, stromal cells and tumor
- Demonstrating recapitulation of the *in vivo* xenograft and patient transcriptional program as well as response to chemotherapeutics at concentrations that correspond to human therapeutic plasma levels
- Highlighting its applications for the development of effective anticancer agents and implications for patient avatars

 Geoffrey Bartholomeusz Associate Professor & Director, Target Identification and Validation Program M.D.Anderson Cancer Center	1.30 Patient-Derived Xenograft Derived Ex Vivo (PDXEX) Models; A Rapid PDX Adaptation for Inflammatory Breast Cancer (IBC) Targeted Drug Identification to Treat Metastatic Disease and Prolong Disease Free Survival of Patients - Evaluating preclinical predictions for the development of combinations for drug resistance metastatic disease - Describing models used and key considerations for experimental design - Model responses and predictability of in-vivo response
 Hongmin Chen Principal Scientist Merck & Co	2.00 Patient Derived Translational 3D Tumor Model for Evaluation of Oncology & Immuno-Oncology Drugs - Evaluating donor differential response of patient derived 3D tumors to chemo treatment, potentially enabling biomarker discovery and patient stratification. - Validating tumor-matching donor immune cell co-culture response to immuno-oncology drugs, correlation to clinical observation - Discussing challenges and potential applications in drug development
	2.30 Afternoon Refreshments & Networking
Assessing Model Design & Needed Complexity for Immuno-Oncology Research	
 Cristina Bertineti-Lapatki Lab Head Mechanistic Safety Roche Pharmaceuticals	3.00 Evaluating Immune-Modulatory Drugs Preclinically Using Microfluidic and Static-Based 3D Cultures
 Roger Kamm Professor - Biological & Mechanical Engineering MIT  Susan Kaufman Senior Scientific Researcher Genentech  Dan Gioeli Associate Professor, Microbiology, Immunology, and Cancer Biology University of Virginia	3.30 Mastermind Summary Panel: Designing & Engineering 3D Systems for Immune Oncology - How do we characterize and assess the degree of capture between the tumor model and original tumor tissue. - Questioning whether we are effectively designing non representative behaviors within our models - Exploring the validation continuum for these systems and assessing how we should seek to balance complexity against functionality? - Discerning the predictive and translational value of current models. - Identifying the need to compromise value for assay cost, throughput, convenience of use
	4.15 Close of Conference

 I appreciated the open dialogue, experience and knowledge sharing. At first I was skeptical about the heavy industry presence but it turned out to be the right choice for the topic being discussed 

3D Tissue Models 2017 Attendee

PROUD TO PARTNER WITH



Expertise Partner

Mitra Biotech is a global leader in advancing

personalised cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumour microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound.

www.mitrabiotech.com



Expertise Partner

Rigenerand is a biotech company conjugating

cGMP-grade cell manufacturing for cells and gene therapies with the design and development of avant-garde biomedical devices for applications in oncology and in tissue regeneration. The unique and proprietary bioreactors platform defined ISOCULT originates different tailored products to support 3D tissue-like cultures grown from either cell lines or patients' primary cells, including cancer, stem and immune cells. This offers a new model to fill the still missing gaps between VITro and viVO: VITVO.

www.rigenerand.it



greiner bio-one

Exhibition Partner

Greiner Bio-One North America, Inc. is a privately held plastic

manufacturing company located in Monroe, NC whose three divisions manufacture a variety of products for the medical and research fields. The manufactured products include plasticware for the cultivation and analysis of cell and tissue cultures, microplates for high-throughput screening related to drug screening, products for blood and specimen collection, tests for the detection of bacteria and viruses, as well as, custom-made products. As an international manufacturer with global reach, Greiner Bio-One provides the manufacturing, distribution logistics and product application support to the world's largest hospitals, pharmaceutical and biotechnology corporations.

www.gbo.com




Exhibition Partner

For more than 25 years, Corning has delivered innovations designed to

advance scientific research in areas like 3D cell culture, drug screening, cancer research, stem cell research, bioprocessing and cell therapy. Corning solutions are used by researchers worldwide to create more in vivo-like environments intended to deliver more biologically relevant results. Corning's product portfolio includes tools like permeable supports, biological and synthetic ECMs, cell culture flasks, filtration systems, reusable glassware, bioprocessing scale-up solutions, assay microplates, and PCR products.


www.corning.com

COMPANIES BY TYPE*



*Expected attendance figures based on actual attendance from 2016 and 2017 3D Tissue Models: Drug Discovery & Development

TYPES OF COMPANIES ATTENDING*



*Expected attendance figures based on actual attendance from 2016 and 2017 3D Tissue Models: Drug Discovery & Development

BECOME A PARTNER



Jennifer MacKay
Partnerships Director

T: +1 617 455 4188

E: sponsor@hansonwade.com

Tel: +1 617 455 4188 Mail: info@hansonwade.com

www.3d-oncology.com 3D Tissue Models: Drug Discovery & Development



READY TO REGISTER?

3 EASY WAYS TO BOOK


www.3d-oncology.com


Tel: +1 617 455 4188


Email: register@hansonwade.com

- 1 Identify the practical applications and true utility of 3D microphysiological models to maximize drug discovery and development within IO
- 2 Hear novel preclinical case studies from leading pharmaceutical organizations to learn how they are reaping the benefits within their oncology and IO research
- 3 Unlock the trapped potential of 3D models to reduce attrition rates within oncology drug discovery and development

SECURE YOUR PLACE

Industry & Academic Pricing	Register & Pay before 13/04/2018	Standard Prices
Conference + 2 Workshops	\$2,897 (Save \$400)	\$3,097
Conference + 1 Workshop	\$2,598 (Save \$300)	\$2,798
Conference Only	\$2,099 (Save \$200)	\$2,299
Workshop Only	\$599	

Model & Solution Provider Pricing	Register & Pay before 13/04/2018	Standard Prices
Conference + 2 Workshops	\$3,797 (Save \$400)	\$3,997
Conference + 1 Workshop	\$3,298 (Save \$300)	\$3,498
Conference Only	\$2,799 (Save \$200)	\$2,999
Workshop Only	\$599	

Team Discounts*


- 10% discount – 2-3 delegates
- 20% discount – 4 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Contact:

register@hansonwade.com

“I appreciated this well-organized conference. It was a great opportunity to learn recent trends and future directions of 3D-tissue culture models”

Kazuhiro Tetsuka, Research Fellow, Astellas Pharma Inc., 3D Tissue Model 2017 Attendee



VENUE

The Sheraton Boston Hotel
39 Dalton Street, Boston
MA, 02199, United States

For further information or assistance, please
www.sheratonbostonhotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

